The investigation of haematological malignancies (cancers of the blood, bone marrow and lymph nodes) represents a significant area of clinical and research activity. Our understanding of how and why blood cancers develop is underpinned by basic research into how blood cells develop normally and what happens at the earliest stage of malignancy. Research is closely aligned with clinical treatment so that patients receive the best diagnostic and therapeutic options based on their particular cancer.
Data integration techniques are being explored in the prospective clinical trial DIRECT (CI: Dr Daniel Hodson).
Further information on the CRUK Cambridge Centre Haematological Malignancies Programme.
The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by affecting patients along their treatment pathway.